Aquestive (AQST) COO Cassie Jung Exercises Warrants

What Happened
Cassie Jung, Chief Operating Officer of Aquestive Therapeutics (AQST), exercised a common stock purchase warrant on September 3, 2026, acquiring 4,587 shares by paying $0.96 per share for a total cash outlay of $4,404. The transaction also shows the associated warrant (the derivative) was disposed/cancelled as part of the exercise.

Key Details

• Transaction date: 2026-09-03; Form 4 filed: 2026-09-08.
• Shares acquired: 4,587 at $0.96 each; total paid: $4,404.
• Derivative disposed: 4,587 units reflected as cancelled/converted at $0.00 (the warrant).
• Footnote: the instrument was a Common Stock Purchase Warrant issued June 8, 2022 (exercisable Dec 8, 2022; expires June 8, 2027; $0.96 exercise price).
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Transaction code: exercise of an in-the-money derivative (warrant). Filing timing: transaction on Sep 3, filed Sep 8 — investors may note the 5-calendar-day gap relative to the typical 2-business-day Form 4 reporting requirement.

Context
This was a cash exercise of a warrant (not a cashless exercise or an open-market sale). Exercises convert a derivative into common shares — a routine capital/action by insiders and not in itself a directional buy/sell opinion. The dollar value here is modest ($4,404), so the trade is small in economic size.